论文部分内容阅读
目的:研究Fas相关死亡域蛋白(FADD)在卵巢癌中的表达,探讨其在卵巢癌发生、发展中的作用及临床意义,并判断卵巢癌的恶性程度、估计其预后。方法:采用SP免疫组织化学方法检测62例卵巢癌、15例卵巢良性肿瘤和16例正常卵巢组织中FADD的表达,并分析卵巢癌的临床病理资料。结果:①正常卵巢组织中FADD阳性表达率为87.5%,卵巢良性肿瘤阳性表达率为73.3%,卵巢癌阳性表达率为32.3%,正常卵巢与卵巢癌中的阳性表达率差异有高度显著性(P<0.01),卵巢良性肿瘤与卵巢癌中的阳性表达率差异亦有高度显著性(P<0.01),而正常卵巢与卵巢良性肿瘤的阳性表达率差异无显著性(P>0.05)。②各组标本中FADD的表达阳性程度较低,并以弱阳性为主(共36例),阳性共11例,强阳性标本数为0。③FADD的阳性表达率在Ⅰ期、Ⅱ期及Ⅲ期和Ⅳ期合并组间比较有显著性差异(P<0.05);FADD的阳性表达率与临床分期呈负相关(P<0.001)。④中分化组与低分化组的FADD的阳性表达明显低于高分化组,差异有高度显著性(P<0.01)。⑤浆液性囊腺癌阳性表达率为31.8%;非浆液性囊腺癌阳性表达率为33.3%。两组FADD的表达无显著性(P>0.05)。结论:FADD在卵巢癌的发生发展中起着重要的作用,根据其表达率的高低可以判断肿瘤的恶性程度,估计卵巢癌的预后,为基因水平治疗卵巢癌提供新的思路。
Objective: To study the expression of Fas-associated death domain protein (FADD) in ovarian cancer and its role in the development and progression of ovarian cancer and its clinical significance, and to determine the malignancy of ovarian cancer and estimate its prognosis. Methods: SP immunohistochemistry was used to detect the expression of FADD in 62 cases of ovarian cancer, 15 cases of benign ovarian tumor and 16 cases of normal ovarian tissue. The clinicopathological data of ovarian cancer were analyzed. Results: ① The positive rate of FADD in normal ovarian tissue was 87.5%, the positive rate of benign ovarian tumor was 73.3%, the positive rate of ovarian cancer was 32.3%, the positive rate of normal ovarian and ovarian cancer was highly significant ( (P <0.01). There was also a significant difference in the positive expression rate between benign ovarian tumor and ovarian cancer (P <0.01), while there was no significant difference between normal ovarian and benign ovarian tumors (P> 0.05). ② The positive expression of FADD in each group was lower than that in normal group (36 cases in total), positive in 11 cases and strong positive samples in 0 cases. (3) The positive rate of FADD was significantly different between the combined stage Ⅰ, Ⅱ, Ⅲ and Ⅳ (P <0.05). The positive rate of FADD was negatively correlated with the clinical stage (P <0.001). ④ The positive expression of FADD in moderately differentiated group and poorly differentiated group was significantly lower than that in well differentiated group, the difference was highly significant (P <0.01). The positive rate of serous cystadenocarcinoma was 31.8%; the positive rate of non-serous cystadenocarcinoma was 33.3%. There was no significant difference in FADD expression between the two groups (P> 0.05). Conclusion: FADD plays an important role in the genesis and development of ovarian cancer. According to the expression of FADD, it can determine the malignant degree of ovarian cancer and estimate the prognosis of ovarian cancer. It provides a new idea for gene therapy for ovarian cancer.